Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: SSP who wrote (40247)	3/30/2000 12:46:00 PM
From: Jim Bishop	Read Replies (1) \| Respond to of 150070

I do believe I've got a fill on some EKSIA at .10, but WebBroker is down, and I'm too lazy to phone them, LOL it'll be a little surprise when I get to the office.

To: SSP who wrote (40247)	3/30/2000 12:58:00 PM
From: Jim Bishop	Respond to of 150070

The Dress Barn, Inc. Announces Completion of $75 Million Stock Repurchase Program and Authorizes an Additional $50 Million Program SUFFERN, N.Y., Mar 30, 2000 /PRNewswire via COMTEX/ -- The Dress Barn, Inc. (Nasdaq: DBRN), one of the largest national specialty store chains offering women's career and casual fashions to the working woman at value prices, today announced that it has completed its Board of Directors authorization to repurchase up to $75 million of Dress Barn Common Stock. The Company repurchased 4,847,600 shares at an average price of $15.47, representing approximately 20% of its outstanding shares. The Company's Board of Directors today approved an additional repurchase of up to $50 million of Dress Barn Common Stock. The repurchases are authorized to be made by the Company from time to time when market conditions warrant. The program provides for the repurchase of Dress Barn Common Stock through open market purchases and/or privately negotiated transactions. Elliot S. Jaffe, Chairman of the Board and Chief Executive Officer of The Dress Barn, Inc., commented: "This new authorization represents our continued commitment to enhance shareholder value. We believe Dress Barn's shares to be undervalued at current price levels. In addition to this program, our ability to generate strong cash flow enables us to fund our new store expansion program, take advantage of new business opportunities, and other anticipated needs of the business." This news release contains forward-looking statements. Important factors which may affect these statements are contained in the Company's Annual Report or Form 10-K for the fiscal year ended July 31, 1999 and may be contained in any subsequent reports filed by the Company with the Securities and Exchange Commission. SOURCE The Dress Barn, Inc. (C) 2000 PR Newswire. All rights reserved. prnewswire.com -0- CONTACT: Armand Correia, Senior Vice President & CFO of The Dress Barn 914-369-4600 KEYWORD: New York INDUSTRY KEYWORD: REA URL: dressbarn.com

To: SSP who wrote (40247)	3/31/2000 9:55:00 AM
From: Witold	Read Replies (2) \| Respond to of 150070

Have you seen BSDM morning PR !!!???!!! Interesting. Related Quotes BSDM.OB 2 9/32 -5/32 delayed 20 mins - disclaimer Friday March 31, 8:09 am Eastern Time Company Press Release SOURCE: BSD Medical Corp. THE LANCET Reports Six Year Study Showing Success in Treating Cervical Cancer - Trials Used BSD-2000 Deep Regional Hyperthermia System SALT LAKE CITY, March 31 /PRNewswire/ -- BSD Medical Corp. (OTC Bulletin Board: BSDM - news) announced today that THE LANCET, the world's longest running medical journal, has issued a press release to approximately 250 mainstream and specialist media contacts announcing the long-awaited results of a six-year cancer study comparing the effectiveness of hyperthermia and radiation (radiotherapy) to radiation treatments alone. The findings of this study are so significant that they are being printed as the lead article in the April 1, 2000 issue of THE LANCET. (See THE LANCET press release at www.thelancet.com). As a peer-reviewed journal with a world following, this report in THE LANCET will be received with great interest and credibility by international readers (about 60% of whom reside in the United States). The trials reported are a randomized, Phase III study performed on 358 human volunteers with cancer. This study involved the BSD-2000, the company's advanced, phase array system for focusing electromagnetic energy waves to heat deep tumors non-invasively (a therapy known as ``hyperthermia'). Although the study showed promise for the treatment of advanced cervical, bladder, and colorectal cancer using hyperthermia, the most remarkable results were obtained in advanced cervical cancer. Complete response rate (disappearance of the tumor) was obtained in 83% of those who received hyperthermia and radiation, compared to 57% of those who were treated with radiation alone. This 46% improvement is not only statistically significant, it is remarkable. In addition, the three-year survival rate for those who received combined treatments nearly doubled (improved 89%), compared to those who received radiation alone. The study was successfully received by the regulatory authorities in The Netherlands, where it was conducted, and has recently led to government approval and reimbursement there for use of hyperthermia in conjunction with radiation in the treatment of cervical cancer. The lead author in this study was Jacoba van der Zee, M. D., who coordinated research at the University Hospital-Daniel den Hoed Cancer Center (Rotterdam) and Academic Medical Center (Amsterdam). Funding for the study, including eleven participating clinical centers, was provided by the Dutch Health Insurance Council. Dr. van der Zee stated, ``In cancer treatment, it is rather unusual to have a modality with the ability to kill tumor cells without damaging the normal tissue. In this study, this expectation turned out to be completely true. There is no nausea or enhancement of side-effects from radiotherapy, and hospitalization is not required for this treatment.' Further information about BSD Medical Corporation and hyperthermia treatment can be found at www.bsdmc.com. Statements contained in this press release that are not historical facts are forward looking statements, as that item is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties (detailed in the Company's filings with the Securities and Exchange Commission) that could cause actual results to differ materially from estimated results.